A detailed history of Bray Capital Advisors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bray Capital Advisors holds 3,930 shares of VRTX stock, worth $1.97 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
3,930
Previous 3,930 -0.0%
Holding current value
$1.97 Million
Previous $1.84 Million 0.81%
% of portfolio
0.46%
Previous 0.48%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 28, 2021

BUY
$181.39 - $202.99 $34,464 - $38,568
190 Added 5.08%
3,930 $713,000
Q2 2021

Jul 28, 2021

BUY
$187.49 - $221.1 $65,621 - $77,385
350 Added 10.32%
3,740 $754,000
Q4 2020

Jan 28, 2021

BUY
$207.01 - $276.09 $179,063 - $238,817
865 Added 34.26%
3,390 $801,000
Q3 2020

Oct 30, 2020

BUY
$255.65 - $303.1 $645,516 - $765,327
2,525 New
2,525 $687,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bray Capital Advisors Portfolio

Follow Bray Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bray Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bray Capital Advisors with notifications on news.